拉米夫定治疗慢性乙型肝炎对血清肝纤维化指标影响的临床观察

Influence on serum hepatic fibrosis index in lamivudine-treated patients with chronic hepatitis B

目的探讨拉米夫定治疗慢性乙型肝炎对患者血清肝纤维化指标的影响。方法对42例慢性乙型肝炎患者在拉米夫定治疗前和治疗1年后测定血清透明质酸(HA)、层粘蛋白(LN)、Ⅲ型前胶原(PCⅢ)和Ⅳ型胶原(ⅣC)水平,并与39例对照组进行比较。结果治疗组治疗后4项血清肝纤维化指标明显下降(P均<0.01);治疗后治疗组与对照组相比也有显著性差异(P均<0.01)。结论拉米夫定治疗慢性乙型肝炎对血清肝纤维化指标有明显降低作用。

Objective To investigate the changes of serum fibrosis markers of lamivudine-treated patients with chronic hepatitis B. Methods 81 patients with chronic hepatitis B were randomly divided into treatment group and control group. The treatment group （42 patients） were treated with lamivudine, while the control group （39 patients） were treated with live-protecting drugs. The levels of serum byaluronic acid （HA）, laminin （LN）, type Ⅲ procollagen （PCⅢ） and type Ⅳ collagen （ⅣC） of each group were detected before and after treatment. Results The level of serum HA, LN, PC Ⅲ and Ⅳ C significantly decreased after the treatment of lamivudine （P〈0. 01） and the level of serum HA, LN, PC Ⅲ and ⅣC of treatment group was obviously different from that of comtrol group after the treatment of lamivudine（P〈0. 01）. Conclusion Lamivudine could obviously decrease the serum hepatic fibrosis index in patients with chronic hepatitis B.